Lee CK, et al. - A prognostic nomogram, with the aim of enhancing the prediction of overall survival (OS) in subjects treated with chemotherapy, was developed and verified by the researchers. Using data from a training cohort of subjects from two trials, including the chemotherapy-only arm in AURELIA and all randomized patients in CARTAXHY, the program was made. The nomogram involved six significant OS predictors, in order of importance, ie, performance status, ascites, size of the largest tumor, CA-125, platinum-free interval, and primary platinum resistance. The median OS was 25.3, 15.2 and 7.4 months in the good, intermediate and poor prognosis groups, respectively, in the training cohort. The median OS was 18.5, 10.3 and 5.8 months in the good, intermediate and poor prognosis groups, respectively, in the PENELOPE validation cohort. The median OS was 26.7, 13.8 and 10.0 months in good, intermediate and poor prognosis groups, respectively, n the AURELIA bevacizumab-chemotherapy validation cohort. Therefore, in platinum-resistant ovarian cancer, the nomogram with six pretreatment characteristics permitted prognostication of OS and could be used for stratification of cases in clinical trials as well as for counseling subjects about prognosis.